Stock comparison
Amicus Therapeutics
Eli Lilly
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
FOLD
Amicus Therapeutics
Market cap
$4.55B
Sector
Healthcare
LLY
Eli Lilly
Market cap
$1T
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | FOLD | LLY | Winner |
|---|---|---|---|
| Warren Buffett | 42D | 72B | LLY |
| Benjamin Graham | 66D | 86A | LLY |
| Philip Fisher |
Side-by-side metrics
| Metric | FOLD | LLY |
|---|---|---|
| Market cap | $4.55B | $1T |
| P/E (TTM) | - | 36.6x |
| EV/EBIT | 139.7x | 34.1x |
| ROIC (TTM) | -6.46% | 32.06% |
| Gross margin | 87.91% | 83.51% |
| Net margin | -4.27% | 34.98% |
| Revenue CAGR 5y | 20.03% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
FOLD leads on
- P/E (TTM)-vs 36.6x+122%
- Gross margin87.91%vs 83.51%+5%
LLY leads on
- Net margin34.98%vs -4.27%+112%
More like LLY
Related on invest-like
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.